[Comment] Antibody–drug conjugates in acute myeloid leukaemia: more research needed

In The Lancet Oncology, Naval G Daver and colleagues1 report the results of a first-in-human, phase 1/2 dose-escalation and dose-expansion study evaluating the safety and antileukaemia activity of pivekimab sunirine (IMGN632) in patients with relapsed or refractory CD123-positive acute myeloid leukaemia aged 18 years or older. Pivekimab sunirine is a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody conjugated to an alkyl-benzodiazepine.2 The primary endpoints of the study were the maximum tolerated dose and recommended phase 2 dose.